Formulation and Specifications: Tablets: 240 mg
Indications: Unresectable or metastatic melanoma positive for BRAF V600 mutation as determined by an assay approved by the State Drug Administration.
Key points for rational drug use:
1. Tumors must be BRAF V600 mutation-positive as determined by a test approved by the State Drug Administration before treatment with vimofenib can be administered, and vimofenib should not be used in patients with BRAF wild-type melanoma. .
2. The recommended dose of vemifenib is 960 mg/dose twice daily (1920 mg total daily dose), and reducing the dose below 480 mg twice daily is not recommended.
3. Common skin reactions such as rash, photosensitivity reactions, etc. must be noted during dosing. .
4. Initiation of vimofenib is not recommended at baseline QTc >500ms, and treatment with vimofenib is not recommended for patients with uncorrectable electrolyte abnormalities, long QTc syndrome, or who are taking medications known to prolong the QTc interval. .
5. There is no evidence of potentiation with vimofenib in combination with epilimumab, and coadministration with epilimumab is not recommended when using vimofenib . .
6. The use of vimofenib is contraindicated in women during pregnancy unless the possible benefit to the mother outweighs the possible risk to the fetus. Vemofenib is not recommended for women who are breastfeeding and the decision to discontinue breastfeeding or discontinue vemofenib therapy must be made after weighing the benefits of breastfeeding for the infant against the benefits of treatment for the mother. 7. Combinations with drugs that are metabolized by CYP1A2 and CYP3A4 and have a narrow therapeutic window of safety are not recommended for the use of vemifenib, and caution should be exercised with the use of potent CYP3A4 inhibitors or inducers with vemifenib.